# CONCEPT MEDICAL ANNOUNCES PRELIMINARY 3-YEAR SIRONA DATA AT CHARING CROSS SYMPOSIUM 2026

- Link: https://www.thailand-business-news.com/pr-news/concept-medical-announces-preliminary-3-year-sirona-data-at-charing-cross-symposium-2026
- Published: 2026-04-27T22:17:00+07:00
- Author: PR Newswire

|   |

LONDON, April 27, 2026 /PRNewswire/ — [Concept Medical Inc.](https://www.conceptmedical.com/),
today announced the presentation of preliminary 3-year follow-up data from the **
SIRONA randomised trial at the Charing Cross (CX) Symposium 2026**, reinforcing 
its leadership in drug-delivery technologies for peripheral interventions.

 [⌊Preliminary 3-Year SIRONA Data Presented at CX-2026 Demonstrates Durable Freedom from Reintervention with MagicTouch PTA in Femoropopliteal Disease⌉](https://mma.prnasia.com/media2/2966154/SIRONA_Trial_Data.jpg?p=medium600)

Preliminary 3-Year SIRONA Data Presented at CX-2026 Demonstrates Durable Freedom
from Reintervention with MagicTouch PTA in Femoropopliteal Disease

The data were presented by **Principal Investigator Prof. Ulf Teichgräber** during
a podium first session on ‘3-year results from the SIRONA randomised trial.’

**SIRONA is a randomised controlled trial evaluating sirolimus-coated versus paclitaxel-
coated balloon angioplasty in femoropopliteal artery disease**, designed to generate
robust head-to-head comparative evidence in a field historically dominated by paclitaxel-
based therapies. Previously in [JACC published 12-month results](https://www.jacc.org/doi/10.1016/j.jacc.2025.12.017)
demonstrated non-inferiority across the trial’s primary efficacy and safety endpoints.

In the current 3-year analysis, [**MagicTouch PTA**](https://www.conceptmedical.com/magictouch-pta/),
a sirolimus-coated balloon, showed **higher freedom from clinically driven target
lesion revascularization (cdTLR)** compared with the paclitaxel-coated balloon group(**
88.2% vs 80.2%; HR 0.60; 95% CI 0.36–0.97; log-rank p=0.03**). The results are pending**
Clinical Events Committee (CEC) adjudication**. Taken together, these preliminary
findings suggest that sirolimus-coated balloon angioplasty may provide more durable
long-term outcomes than paclitaxel-coated balloon angioplasty.

At 3 years, Freedom of **all-cause mortality remained comparable** between treatment
groups (**92.6% vs 92.6%; HR 1.12; p=0.67**), supporting a balanced long-term safety
profile. Rates of Freedom of **major amputation were low**, with **no statistically
significant difference observed** between groups (**99.6% vs 99.6%;** **HR 0.54;
p=0.61**).

**Prof. Ulf Teichgräber**, Principal Investigator, said, "The preliminary 3-year
SIRONA data are very exciting. Seeing a sustained reduced reduction in cdTLR with
[MagicTouch PTA](https://www.conceptmedical.com/magictouch-pta/) over such a long
follow-up period is highly encouraging and speaks to the durability of sirolimus-
based drug delivery in femoropopliteal interventions. These findings add important
long-term randomized evidence to the field and, pending final CEC adjudication, 
represent a very promising signal for the future role of sirolimus-coated balloons
in peripheral artery disease. Importantly, these findings should not be interpreted
as a class effect, but rather highlight the need to evaluate individual sirolimus-
coated balloon technologies based on robust clinical evidence."

**Dr Manish Doshi**, Founder and Managing Director, Concept Medical, added, "For
us, SIRONA represents the discipline of long-term clinical science, going beyond
early outcomes to truly understand durability. These 3-year findings continue to
strengthen the comparative evidence for sirolimus-coated balloon therapy. As we 
scale globally, our focus remains on generating high-quality, long-term data that
clinicians can rely on with confidence."

**About Concept Medical**

Concept Medical Inc. is a global pioneer in drug-delivery technologies for vascular
interventions. The company is headquartered in Florida, USA, with manufacturing 
operations in India. Its proprietary [**Nanolute™ technology platform**](https://www.conceptmedical.com/nanolute-technology/)
is designed to enable controlled and sustained delivery of sirolimus across coronary
and peripheral applications. The company’s flagship product, [MagicTouch](https://www.conceptmedical.com/drug-coated-balloon-dcb/),
is among the most clinically studied sirolimus-coated balloon platforms worldwide.

**Source: **Data from the **SIRONA randomised trial**, presented by **Prof. Ulf 
Teichgräber** at the **Charing Cross (CX) Symposium 2026**, London, UK. Preliminary
results prior to Clinical Events Committee (CEC) adjudication.

Photo: [https://mma.prnasia.com/media2/2966154/SIRONA_Trial_Data.jpg?p=medium600](https://mma.prnasia.com/media2/2966154/SIRONA_Trial_Data.jpg?p=medium600)

Logo: [https://mma.prnasia.com/media2/1926812/5938255/Concept_Medical_Logo.jpg?p=medium600](https://mma.prnasia.com/media2/1926812/5938255/Concept_Medical_Logo.jpg?p=medium600)

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [CONCEPT MEDICAL ANNOUNCES PRELIMINARY 3-YEAR SIRONA DATA AT CHARING CROSS SYMPOSIUM 2026 ](http://www.prnasia.com/story/archive/4943887_AE43887_0?rand=184833)